Want to see ILMN full AI Analyst Report?
Revenue by Segment
Analyzes sales across various business divisions, indicating which areas are performing well and contributing most to overall growth.
Core Illumina is the clear, stable revenue engine while the small Grail contribution vanishes late‑2024 and historical eliminations normalize—simplifying the top‑line and concentrating growth risk/reward in core sequencing consumables and NovaSeq X adoption. Management’s call backs up this shift (clinical consumables strength, rapid X placements and raised guidance), but persistent research & applied weakness and supply constraints on X mean instrument revenue and organic growth may stay lumpy near term; sustained margin upside depends on consumables mix and scaling X supply.
ILMN Revenue by Segment
| Date | Eliminations | Core Illumina | Grail |
|---|---|---|---|
| Jun 28, 2026 | $0.00 | $1.16B | $0.00 |
| Mar 29, 2026 | $0.00 | $1.09B | $0.00 |
| Dec 28, 2025 | $0.00 | $1.16B | $0.00 |
| Sep 28, 2025 | $0.00 | $1.08B | $0.00 |
| Jun 30, 2025 | $0.00 | $1.06B | $0.00 |
| Mar 31, 2025 | $0.00 | $1.04B | $0.00 |
| Dec 29, 2024 | $15.00M | $1.10B | -$1.00M |
| Sep 29, 2024 | $0.00 | $1.08B | $0.00 |
| Jun 30, 2024 | -$9.00M | $1.09B | $29.00M |
| Mar 31, 2024 | -$7.00M | $1.06B | $27.00M |
| Dec 31, 2023 | -$5.00M | $1.10B | $30.00M |
| Oct 01, 2023 | -$8.00M | $1.11B | $21.00M |
| Jul 02, 2023 | -$5.00M | $1.16B | $22.00M |
| Apr 02, 2023 | -$9.00M | $1.08B | $20.00M |
| Jan 01, 2023 | -$5.00M | $1.07B | $23.00M |
| Oct 02, 2022 | -$5.00M | $1.11B | $10.00M |
| Jul 03, 2022 | -$6.00M | $1.16B | $12.00M |
| Apr 03, 2022 | -$8.00M | $1.22B | $10.00M |
| Jan 02, 2022 | $0.00 | $1.19B | $10.00M |
| Oct 03, 2021 | $0.00 | $1.11B | $2.00M |
| Jul 04, 2021 | $0.00 | $1.13B | $0.00 |
| Apr 04, 2021 | $0.00 | $1.09B | $0.00 |
| Jan 03, 2021 | $0.00 | $953.00M | $0.00 |
| Sep 27, 2020 | $0.00 | $794.00M | $0.00 |
| Jun 28, 2020 | $0.00 | $633.00M | $0.00 |
| Mar 29, 2020 | $0.00 | $859.00M | $0.00 |
